AU2019323501B2 - Recombinant human type II mitochondrial dynein-like GTPase gene sequence and application thereof - Google Patents

Recombinant human type II mitochondrial dynein-like GTPase gene sequence and application thereof Download PDF

Info

Publication number
AU2019323501B2
AU2019323501B2 AU2019323501A AU2019323501A AU2019323501B2 AU 2019323501 B2 AU2019323501 B2 AU 2019323501B2 AU 2019323501 A AU2019323501 A AU 2019323501A AU 2019323501 A AU2019323501 A AU 2019323501A AU 2019323501 B2 AU2019323501 B2 AU 2019323501B2
Authority
AU
Australia
Prior art keywords
sequence
nucleic acid
vector
recombinant nucleic
gtpase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019323501A
Other languages
English (en)
Other versions
AU2019323501A1 (en
Inventor
Bin Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Neurophth Biotechnology Ltd Co
Original Assignee
Wuhan Neurophth Biotechnology Ltd Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Neurophth Biotechnology Ltd Co filed Critical Wuhan Neurophth Biotechnology Ltd Co
Publication of AU2019323501A1 publication Critical patent/AU2019323501A1/en
Application granted granted Critical
Publication of AU2019323501B2 publication Critical patent/AU2019323501B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/03—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; catalysing transmembrane movement of substances (3.6.3)
    • C12Y306/03005—Zn2+-exporting ATPase (3.6.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05005—Dynamin GTPase (3.6.5.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019323501A 2018-08-23 2019-08-23 Recombinant human type II mitochondrial dynein-like GTPase gene sequence and application thereof Active AU2019323501B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810968173.0A CN110857440B (zh) 2018-08-23 2018-08-23 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
CN201810968173.0 2018-08-23
PCT/CN2019/102352 WO2020038473A1 (zh) 2018-08-23 2019-08-23 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用

Publications (2)

Publication Number Publication Date
AU2019323501A1 AU2019323501A1 (en) 2021-02-25
AU2019323501B2 true AU2019323501B2 (en) 2023-08-03

Family

ID=69592310

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019323501A Active AU2019323501B2 (en) 2018-08-23 2019-08-23 Recombinant human type II mitochondrial dynein-like GTPase gene sequence and application thereof

Country Status (11)

Country Link
US (1) US11459584B2 (https=)
EP (1) EP3851535A4 (https=)
JP (1) JP7285022B2 (https=)
KR (1) KR102612148B1 (https=)
CN (1) CN110857440B (https=)
AU (1) AU2019323501B2 (https=)
BR (1) BR112021002566A2 (https=)
CA (1) CA3110153A1 (https=)
MX (1) MX2021002135A (https=)
SG (1) SG11202101236WA (https=)
WO (1) WO2020038473A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110857440B (zh) 2018-08-23 2021-02-19 武汉纽福斯生物科技有限公司 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用
CN111849998A (zh) * 2020-07-29 2020-10-30 武汉纽福斯生物科技有限公司 编码人卵黄状黄斑病蛋白1的核酸分子及其应用
CN117904156A (zh) * 2022-10-17 2024-04-19 武汉纽福斯生物科技有限公司 人线粒体动力蛋白样gtp酶及应用
WO2024226729A2 (en) * 2023-04-26 2024-10-31 Astellas Gene Therapies, Inc. Compositions and methods for opa1 gene therapy
CN117304293B (zh) * 2023-10-07 2025-08-08 浙江大学 一种鸡opa1抗原决定簇及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
EP1771571A2 (en) 2004-07-30 2007-04-11 Targeted Genetics Corporation Recombinant aav based vaccine methods
PT1880008E (pt) * 2005-05-03 2015-08-27 Inserm Inst Nat De La Santé Et De La Rech Médicale Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada
WO2007134818A2 (en) * 2006-05-18 2007-11-29 Univ Muenchen L Maximilians Method for diagnosing mitochondrial dysfunction
CN102634527B (zh) * 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
AU2013293270B2 (en) * 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
AR095983A1 (es) * 2013-04-03 2015-11-25 Aliophtha Ag Factores artificiales de transcripción para el tratamiento de enfermedades causadas por haploinsuficiencia de opa1
CN104450747B (zh) * 2014-09-23 2018-02-09 武汉纽福斯生物科技有限公司 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂
EP3289080B1 (en) * 2015-04-30 2021-08-25 The Trustees of Columbia University in the City of New York Gene therapy for autosomal dominant diseases
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
EP3548039B1 (en) * 2016-12-04 2023-07-19 Alavi Khorassani Moghadam, Marcel Victor Ribavirin for use in the treatment of a mitochondrial disease
WO2018146588A1 (en) 2017-02-08 2018-08-16 Friedrich Miescher Institute For Biomedical Research Synp88, a promoter for the specific expression of genes in retinal ganglion cells
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
CN110857440B (zh) 2018-08-23 2021-02-19 武汉纽福斯生物科技有限公司 重组人ⅱ型线粒体动力蛋白样gtp酶基因序列及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq FOTIN-MLECZEK M : "human therapeutic protein OPA1 RNA SEQ ID 20917", XP055975072, retrieved from EBI *
DEL DOTTO VALENTINA ET AL: "Eight human OPA1 isoforms, long and short: What are they for?", BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGETICS, 1 April 2018, 1859(4):263-269, DOI: 10.1016/j.bbabio.2018.01.005 *

Also Published As

Publication number Publication date
CN110857440B (zh) 2021-02-19
EP3851535A1 (en) 2021-07-21
SG11202101236WA (en) 2021-03-30
KR102612148B1 (ko) 2023-12-12
BR112021002566A2 (pt) 2021-06-22
JP2021533801A (ja) 2021-12-09
CA3110153A1 (en) 2020-02-27
US11459584B2 (en) 2022-10-04
CN110857440A (zh) 2020-03-03
AU2019323501A1 (en) 2021-02-25
EP3851535A4 (en) 2022-12-14
MX2021002135A (es) 2021-06-23
WO2020038473A1 (zh) 2020-02-27
US20210180086A1 (en) 2021-06-17
KR20210049131A (ko) 2021-05-04
JP7285022B2 (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
AU2019323501B2 (en) Recombinant human type II mitochondrial dynein-like GTPase gene sequence and application thereof
CN109476707B (zh) 腺相关病毒变体衣壳和其使用方法
JP2024015194A (ja) アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
JP2023126919A (ja) バリアントカプシドを有するアデノ随伴ウイルスビリオン及びその使用方法
CN111621502B (zh) 视网膜劈裂蛋白的编码序列、其表达载体构建及其应用
JP2021168670A (ja) １色覚および他の疾患の治療のためのプロモーター、発現カセット、ベクター、キット、ならびに方法
CN114127296B (zh) Ube3a基因和表达盒及其应用
EP3875588A1 (en) Gene therapy vector for treating retinitis pigmentosa disease
CN113025633A (zh) 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR20230061372A (ko) 코돈 최적화된 rpgrorf15 유전자 및 이의 용도
WO2025247393A1 (zh) 用于治疗Prom1相关视网膜疾病的新型治疗药物
CN110699367B (zh) 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
CN111926021B (zh) 重组人norrin胱氨酸结生长因子表达载体及其应用
WO2020077756A1 (zh) Nd4蛋白的编码序列及其应用
WO2020010491A1 (zh) 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用
WO2020000641A1 (zh) 编码人nadh脱氢酶亚单位蛋白的核酸及其应用
CN111518813B (zh) 视紫红质的编码序列、其表达载体构建及其应用
JP2024517957A (ja) ベクター系
HK40056038A (en) Recombinant human type ii mitochondrial dynein-like gtpase gene sequence and application thereof
JP2023528139A (ja) ヒト核因子ｅ２関連因子２の発現ベクター及び発現ベクターの適用
CN111909935B (zh) 重组人卷曲蛋白受体4(fzd4)的表达载体及其应用
HK40092218A (zh) 腺相关病毒变体衣壳和其使用方法
HK40091836A (zh) 腺相关病毒变体衣壳和其使用方法
WO2024083013A1 (zh) 人线粒体动力蛋白样gtp酶及应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)